Immuno-Oncology Overview 2017: CAR-T Cell Therapy Early Clinical Results are Extremely Promising –

DUBLIN–()–The “Immuno-Oncology
report has been added to’s

This is an overview of the field of immuno-oncology and the various
immuno-oncology classes. Immuno-oncology is one of the most promising
and fastest growing areas of cancer research, as well as one of the most
active areas in terms of licensing deals and acquisitions.


  • The PD-1/PD-L1 inhibitor and TCR/CAR-T therapy drug classes lead the
    development of all immuno-oncology drugs. However, several novel
    mechanisms of action are also in early-phase development.
  • Developers of approved PD-1/PD-L1 inhibitors – Bristol-Myers Squibb,
    Merck & Co, Roche, AstraZeneca, and Pfizer – currently dominate the
    immuno-oncology field in terms of the number of ongoing, conducted,
    and planned trials.
  • Furthermore, PD-1/PD-L1 inhibitors remain a focal point of
    immuno-oncology combinations, with various types of combination
    approaches being studied.

Key Topics Covered:

  1. Executive Summary
  2. Immuno-Oncology Overview
  3. Current Status Of Immuno-Oncology Development
  4. Pd-1/Pd-L1 Inhibitors
  5. Ctla-4 Inhibitors
  6. Tcr And Car-T Therapies
  7. Ido Inhibitors
  8. Emerging Drug Classes
  9. Bristol-Myers Squibb
  10. Merck & Co
  11. Roche
  12. Astrazeneca
  13. Pfizer
  14. Immuno-Oncology Combinations
  15. Kol Survey
  16. Kol Interviews

For more information about this report visit

Source link

more recommended stories

Social Media Auto Publish Powered By :
%d bloggers like this: